Reporting from ESMO Congress 2023 in Madrid, Nicolas Girard discusses the results from two important studies on amivantamab in combination therapy for first-line treatment of patients with EGFR-mutated, advanced NSCLC

Abstracts discussed:
- LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial, presented by B.C. Cho

- LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study, presented by Nicolas Girard
Simultaneous publication in the NEJM: https://www.nejm.org/doi/full/10.1056...

Produced by the European Society for Medical Oncology
https://oncologypro.esmo.org